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Subacute thrombosis after primary percutaneous 
coronary intervention with bioresorbable  
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Everolimus-eluting bioresorbable vascular scaffold (BVS) is a promising new technology recently applied in the treatment 
of coronary artery lesions that might overcome the limitations of the currently used drug eluting stents. There were no 
scaffold thromboses reported in the first-in-human trials with BVS implantation. However, the current body of evidence 
on its safety and incidence of early thrombotic complications in the setting of acute coronary syndromes is still limited. We 
present the case of a 58-year-old male who was admitted to a coronary care unit due to typical (two-hour long) chest pain 
with electrocardiographic signs of anterior wall ST segment-elevation myocardial infarction. Coronary angiography revealed 
critical stenosis of the proximal left anterior 
descending artery (Fig. 1A). Subsequent 
primary angioplasty with manual aspiration 
thrombectomy, balloon predilatation, and 
implantation of BVS (ABSORB, 3.5/28 mm, 
12 atm.) was performed, with good angio-
graphic result (TIMI 3 flow) (Fig. 1B). Optical 
coherence tomography (OCT) confirmed 
good scaffold expansion and complete strut 
apposition (Fig. 1C–F). Further in-hospital 
course was uneventful and the patient was 
discharged after five days of hospitalisation. 
On the ninth day after BVS implantation 
he presented again with acute severe chest 
pain and anterior ST-segment elevation in 
electrocardiogram. The patient confirmed 
that he discontinued both antiplatelet drugs 
(aspirin and clopidogrel) after discharge. 
Repeat coronary angiography revealed 
a subacute scaffold thrombosis (Fig. 2A). 
Manual aspiration thrombectomy, abcixi-
mab infusion, and plain old balloon angio-
plasty was performed (Fig. 2B), with good 
final angiographic result (TIMI 3) (Fig. 2C). 
Echocardiography revealed an impaired 
left ventricular ejection fraction of 38%, 
compared to 50% directly after the primary 
index procedure. As there was appropriate 
scaffold expansion and strut apposition in 
OCT directly after the index procedure, the 
most likely cause of scaffold thrombosis was 
the cessation of antiplatelet therapy.
Figure 2. A. Occlusion of the proximal left anterior descending artery in the 
place of bioresorbable vascular scaffold implantation (arrow); B. Plain old 
balloon angioplasty performed in the occluded left anterior descending artery;  
C. Good final angiographic result of the treatment of scaffold thrombosis (TIMI 3)
Figure 1. A. Coronary angiography revealing critical stenosis of the proximal 
left anterior descending artery (arrow); B. Good angiographic result of pri-
mary angioplasty with bioresorbable vascular scaffold implantation (TIMI 3);  
C–F. Good scaffold expansion and complete strut apposition in optical cohe-
rence tomography
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